May 11, 2023
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 11, 2023
Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile
April 19, 2023
Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting
April 17, 2023
Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events
April 6, 2023
Praxis Precision Medicines to Present at 22nd Annual Needham Virtual Healthcare Conference
March 3, 2023
Praxis Precision Medicines to Present at Upcoming Investor Conferences
March 3, 2023
Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3
February 7, 2023
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results